ImmuCell Corporation (ICCC): Price and Financial Metrics
GET POWR RATINGS... FREE!
ICCC Stock Summary
- Immucell Corp's market capitalization of $72,928,359 is ahead of only 12.19% of US-listed equities.
- With a price/earnings ratio of 2,003.31, Immucell Corp P/E ratio is greater than that of about 99.6% of stocks in our set with positive earnings.
- Price to trailing twelve month operating cash flow for ICCC is currently 139.57, higher than 96.81% of US stocks with positive operating cash flow.
- Stocks that are quantitatively similar to ICCC, based on their financial statements, market capitalization, and price volatility, are SRDX, NXGN, TSEM, SRI, and CSBR.
- ICCC's SEC filings can be seen here. And to visit Immucell Corp's official web site, go to immucell.com.
ICCC Valuation Summary
- In comparison to the median Healthcare stock, ICCC's price/earnings ratio is 547.67% lower, now standing at -163.4.
- ICCC's EV/EBIT ratio has moved down 172.5 over the prior 243 months.
- Over the past 243 months, ICCC's price/sales ratio has gone up 3.4.
Below are key valuation metrics over time for ICCC.
| Stock | Date | P/S | P/B | P/E | EV/EBIT |
|---|---|---|---|---|---|
| ICCC | 2021-08-31 | 4.4 | 2.2 | -163.4 | -164.0 |
| ICCC | 2021-08-30 | 4.3 | 2.2 | -161.3 | -161.9 |
| ICCC | 2021-08-27 | 4.2 | 2.1 | -156.9 | -157.4 |
| ICCC | 2021-08-26 | 4.3 | 2.2 | -160.6 | -161.2 |
| ICCC | 2021-08-25 | 4.2 | 2.1 | -154.8 | -155.3 |
| ICCC | 2021-08-24 | 4.1 | 2.0 | -152.3 | -152.8 |
ICCC Growth Metrics
- The 3 year price growth rate now stands at -7.32%.
- Its 4 year revenue growth rate is now at 40.63%.
- Its 3 year net income to common stockholders growth rate is now at -264.84%.
The table below shows ICCC's growth in key financial areas (numbers in millions of US dollars).
| Date | Revenue | Operating Cash Flow | Net Income to Common Stock |
|---|---|---|---|
| 2021-09-30 | 17.54247 | 0.522525 | 0.036404 |
| 2021-06-30 | 16.11482 | -0.403793 | -0.434248 |
| 2021-03-31 | 14.53896 | -0.165421 | -1.341154 |
| 2020-12-31 | 15.3422 | 1.315578 | -1.022117 |
| 2020-09-30 | 15.23075 | 1.112708 | -1.521399 |
| 2020-06-30 | 14.47873 | 1.713629 | -1.701046 |
ICCC Price Target
For more insight on analysts targets of ICCC, see our ICCC price target page. And for a list of of all stocks sorted by upside potential based on analyst target price, see our Top Price Target page.
| Average Price Target | $14.00 | Average Broker Recommendation | 1.5 (Moderate Buy) |
ICCC Stock Price Chart Interactive Chart >
ICCC Price/Volume Stats
| Current price | $8.34 | 52-week high | $10.96 |
| Prev. close | $8.35 | 52-week low | $7.30 |
| Day low | $8.16 | Volume | 1,700 |
| Day high | $8.35 | Avg. volume | 11,557 |
| 50-day MA | $9.05 | Dividend yield | N/A |
| 200-day MA | $8.88 | Market Cap | 64.58M |
ImmuCell Corporation (ICCC) Company Bio
ImmuCell Corporation, an animal health company, acquires, develops, manufactures, and sells products that enhance the health and productivity of dairy and beef cattle in the United States and internationally. It offers First Defense, an orally delivered scours preventive product for calves; and Tri-Shield First Defense, a passive antibody product for the treatment of E. coli, coronavirus, and rotavirus. The company also provides California Mastitis Test that is used to detect somatic cell counts in milk, as well as to determine, which quarter of the udder is mastitic; and Dual-Force First Defense, including a whey protein concentrate for the nutritional and feed supplement markets. In addition, it is involved in developing Re-Tain, a Nisin-based intramammary treatment of subclinical mastitis in lactating dairy cows. The company sells its products through animal health distributors. ImmuCell Corporation was founded in 1982 and is headquartered in Portland, Maine.
Latest ICCC News From Around the Web
Below are the latest news stories about Immucell Corp that investors may wish to consider to help them evaluate ICCC as an investment opportunity.
ImmuCell (NASDAQ:ICCC) Has A Somewhat Strained Balance SheetWarren Buffett famously said, 'Volatility is far from synonymous with risk.' It's only natural to consider a company's... |
ImmuCell Corp (ICCC) CEO Michael Brigham Q4 2021 Results Earnings Call TranscriptNo summary available. |
ImmuCell Announces Unaudited Financial Results for the Quarter and Year Ended December 31, 2021Annual Product Sales for 2021 Increased 25% over 2020PORTLAND, Maine, Feb. 22, 2022 (GLOBE NEWSWIRE) -- ImmuCell Corporation (Nasdaq: ICCC) (“ImmuCell” or the “Company”), a growing animal health company that develops, manufactures and markets scientifically proven and practical products that improve the health and productivity of dairy and beef cattle, today announced its unaudited financial results for the quarter and year ended December 31, 2021. Product Sales Results: During the three-month p |
ImmuCell to Announce Unaudited Financial Results for the Quarter and Year Ended December 31, 2021Conference Call Scheduled for Wednesday, February 23, 2022 at 9:00 AM ETPORTLAND, Maine, Feb. 16, 2022 (GLOBE NEWSWIRE) -- ImmuCell Corporation (Nasdaq: ICCC) (“ImmuCell” or the “Company”), a growing animal health company that develops, manufactures and markets scientifically-proven and practical products that improve the health and productivity of dairy and beef cattle, expects to report unaudited financial results for the quarter and year ended December 31, 2021 after the market closes on Tues |
ImmuCell Announces Record Preliminary, Unaudited Sales Results for the Year Ended December 31, 2021PORTLAND, Maine, Jan. 05, 2022 (GLOBE NEWSWIRE) -- ImmuCell Corporation (Nasdaq: ICCC) (“ImmuCell” or the “Company”), a growing animal health company that develops, manufactures and markets scientifically-proven and practical products that improve the health and productivity of dairy and beef cattle, today announced preliminary, unaudited sales results for the year ended December 31, 2021. Preliminary, Unaudited Total Sales Results: 2021 2020 $ Increase % IncreaseDuring the Quarters Ended Decemb |
ICCC Price Returns
| 1-mo | -14.90% |
| 3-mo | 1.21% |
| 6-mo | -7.33% |
| 1-year | -14.64% |
| 3-year | 35.39% |
| 5-year | 34.95% |
| YTD | 4.25% |
| 2021 | 34.46% |
| 2020 | 15.53% |
| 2019 | -26.95% |
| 2018 | -19.80% |
| 2017 | 47.73% |
Continue Researching ICCC
Want to see what other sources are saying about Immucell Corp's financials and stock price? Try the links below:Immucell Corp (ICCC) Stock Price | Nasdaq
Immucell Corp (ICCC) Stock Quote, History and News - Yahoo Finance
Immucell Corp (ICCC) Stock Price and Basic Information | MarketWatch
Loading social stream, please wait...